Carisma Therapeutics

Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), in collaboration with Moderna, Inc. (Nasdaq: MRNA), has announced promising pre-clinical results for their innovative anti-GPC3 chimeric antigen receptor macrophage (CAR-M) therapy targeting …

Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy Read More